Physician profile
Wael Tello
NPI 1336138577
$9,048.07
in general payments reported to CMS, 2019-2025
25 companies · $4,527 in 2025
The $4,527 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,979 · 2020: $642 · 2021: $32.60 · 2022: $161 · 2023: $694 · 2024: $1,013 · 2025: $4,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,521 · Travel and Lodging: $1,678 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.11 |
| Travel and Lodging | $1,678.12 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,366.87 | 2024-2025 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $1,143.47 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Olympus Corporation of The Americas | $930.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $877.21 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $655.62 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $371.11 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $358.05 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $325.53 | 2019-2025 | Opsynvi |
| Amgen INC. | $299.18 | 2023-2025 | Tezspire |
| Verona Pharma, INC. | $245.76 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $191.62 | 2019-2020 | |
| Genentech USA, INC. | $184.97 | 2019-2022 | |
| Electromed, INC. | $134.93 | 2024-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $130.24 | 2025 | Dupixent |
| United Therapeutics Corporation | $122.79 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $120.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $119.45 | 2024 | Winrevair |
| Sunovion Pharmaceuticals INC. | $110.41 | 2019 | |
| Baxter Healthcare | $95.80 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $66.60 | 2019-2025 | Vest Therapy Und |
| Shire North American Group INC | $63.47 | 2019 | |
| Inogen, INC. | $46.99 | 2022-2025 | |
| Grifols USA, LLC | $44.36 | 2020-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $25.30 | 2020-2025 | Glassia |
| Viatris Specialty LLC | $17.11 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Tello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.